A conversation between two (white) activists to further the dialogue around inclusivity in the field of psychedelic research and culture.

As the psychedelic pharmaceutical industry increasingly prioritizes personal data extraction through mobile apps, wearables, and so-called “targeted” medicine, a recent data breach by former MAPS Canada Executive Director Mark Haden provides a warning about some of the possible consequences to the financial incentives of datafication.

From cultural appropriation to “Shroom Boom,” psychedelic online marketing gaffes and misrepresentations are becoming more and more prevalent from major psychedelic organizations.

In response to the coronavirus pandemic, Christian Angermayer—the world's largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences—dismisses medical experts in his desperation to reboot the economy.

Open Letter to MAPS Canada, MAPS, and MAPS PBC on Data Privacy and Doxxing. We believe that an organization responsible for private data, in such close proximity to criminalized subcultures, must take matters of privacy and security seriously.

In response to the The New York Times February 4 article, "How a Leftist Activist Group Helped Torpedo a Psychedelic Therapy," Psymposia requested corrections to numerous errors and false accusations.

Trump signed into law the First Step Act, which makes modest reforms that ease the federal prison population.

A mining firm’s conflict with Argentinian communities illustrates extractive industry’s practices and values, and raises questions about how these corporate approaches will translate into the psychedelic pharmaceutical industry.

A new website — whoisjoeschraube.com — alleges that Joe Schraube and Miguel Delgado have taken advantage of positions of power and abused people under the influence of psychedelics.

DoubleBlind claims its recently-unveiled New York City billboard is a lot of things, except what it actually is: a giant advertisement.